These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34077738)

  • 21. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
    Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
    Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract.
    Kuo ZK; Lin MW; Lu IH; Yao HJ; Wu HC; Wang CC; Lin SH; Wu SY; Tong TS; Cheng YC; Yen JH; Ko CH; Chiou SJ; Pan IH; Tseng HW
    BMC Complement Altern Med; 2016 Aug; 16():277. PubMed ID: 27502492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
    Arnst KE; Wang Y; Lei ZN; Hwang DJ; Kumar G; Ma D; Parke DN; Chen Q; Yang J; White SW; Seagroves TN; Chen ZS; Miller DD; Li W
    Mol Pharmacol; 2019 Jul; 96(1):73-89. PubMed ID: 31043459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antivascular and antitumor properties of the tubulin-binding chalcone TUB091.
    Canela MD; Noppen S; Bueno O; Prota AE; Bargsten K; Sáez-Calvo G; Jimeno ML; Benkheil M; Ribatti D; Velázquez S; Camarasa MJ; Díaz JF; Steinmetz MO; Priego EM; Pérez-Pérez MJ; Liekens S
    Oncotarget; 2017 Feb; 8(9):14325-14342. PubMed ID: 27224920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COH-203, a novel microtubule inhibitor, exhibits potent anti-tumor activity via p53-dependent senescence in hepatocellular carcinoma.
    Qi H; Zuo DY; Bai ZS; Xu JW; Li ZQ; Shen QR; Wang ZW; Zhang WG; Wu YL
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):262-8. PubMed ID: 25449279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
    Zhong L; Fu XY; Zou C; Yang LL; Zhou S; Yang J; Tang Y; Cheng C; Li LL; Xiang R; Chen LJ; Chen YZ; Wei YQ; Yang SY
    Int J Cancer; 2014 Dec; 135(12):2972-83. PubMed ID: 24789676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thieno[2,3-c]isoquinolines: A novel chemotype of antiproliferative agents inducing cellular apoptosis while targeting the G2/M phase and Tubulin.
    Marae IS; Maklad RM; Samir S; Bakhite EA; Sharmoukh W
    Drug Dev Res; 2023 Jun; 84(4):747-766. PubMed ID: 36999479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway.
    Mao J; Wang D; Wang Z; Tian W; Li X; Duan J; Wang Y; Yang H; You L; Cheng Y; Bian J; Chen Z; Yang Y
    Cancer Lett; 2016 Sep; 380(1):134-43. PubMed ID: 27349166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma.
    Zhou Q; Ching AK; Leung WK; Szeto CY; Ho SM; Chan PK; Yuan YF; Lai PB; Yeo W; Wong N
    Int J Oncol; 2011 Mar; 38(3):721-31. PubMed ID: 21240457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080.
    Qiao F; Zuo D; Shen X; Qi H; Wang H; Zhang W; Wu Y
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):259-70. PubMed ID: 22752214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
    Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
    Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological evaluation of new 2-methoxyestradiol derivatives: Potent inhibitors of angiogenesis and tubulin polymerization.
    Sun M; Zhang Y; Qin J; Ba M; Yao Y; Duan Y; Liu H; Yu D
    Bioorg Chem; 2021 Aug; 113():104988. PubMed ID: 34034135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5-(Furan-2-yl)-4-(3,4,5-trimethoxyphenyl)-3H-1,2-dithiol-3-one oxime (6f), a new synthetic compound, causes human fibrosarcoma HT-1080 cell apoptosis by disrupting tubulin polymerisation and inducing G2/M arrest.
    Zuo D; Pang L; Shen J; Guan Q; Bai Z; Zhang H; Li Y; Lu G; Zhang W; Wu Y
    Int J Oncol; 2017 Jun; 50(6):2069-2078. PubMed ID: 28440465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
    Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
    Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological evaluation of a novel tubulin inhibitor SKLB0565 targeting the colchicine binding site.
    Hu X; Li L; Zhang Q; Wang Q; Feng Z; Xu Y; Xia Y; Yu L
    Bioorg Chem; 2020 Apr; 97():103695. PubMed ID: 32120073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of novel vinyl sulfone derivatives as anti-tumor agents with microtubule polymerization inhibitory and vascular disrupting activities.
    Li W; Yin Y; Yao H; Shuai W; Sun H; Xu S; Liu J; Yao H; Zhu Z; Xu J
    Eur J Med Chem; 2018 Sep; 157():1068-1080. PubMed ID: 30176537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SKLB-14b, a novel oral microtubule-destabilizing agent based on hydroxamic acid with potent anti-tumor and anti-multidrug resistance activities.
    Zhang W; Yang L; Si W; Tang M; Bai P; Zhu Z; Kuang S; Liu J; Shi M; Huang J; Chen X; Li D; Wen Y; Yang Z; Xiao K; Chen L
    Bioorg Chem; 2022 Nov; 128():106053. PubMed ID: 35964504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells.
    Galmarini CM; Martin M; Bouchet BP; Guillen-Navarro MJ; Martínez-Diez M; Martinez-Leal JF; Akhmanova A; Aviles P
    BMC Cancer; 2018 Feb; 18(1):164. PubMed ID: 29415678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo.
    Wang SW; Pan SL; Huang YC; Guh JH; Chiang PC; Huang DY; Kuo SC; Lee KH; Teng CM
    Mol Cancer Ther; 2008 Feb; 7(2):350-60. PubMed ID: 18281518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.